Eritoran

Eritoran is an investigational drug for the treatment of severe sepsis, an excessive inflammatory response to an infection.

In a phase III clinical trial, eritoran did not perform better than existing treatments for the treatment of sepsis.

It was being developed by the Japanese pharmaceutical company Eisai Co. and administered intravenously as the sodium salt eritoran tetrasodium.